| Document Type
|
:
|
BL
|
| Record Number
|
:
|
882553
|
| Title & Author
|
:
|
Behavioral neurobiology of psychedelic drugs /\ Adam L. Halberstadt, Franz X. Vollenweider, David E. Nichols, editors.
|
| Publication Statement
|
:
|
Berlin, Germany :: Springer,, 2018.
|
| Series Statement
|
:
|
Current topics in behavioral neurosciences,; volume 36
|
| Page. NO
|
:
|
1 online resource (x, 430 pages) :: illustrations (some color)
|
| ISBN
|
:
|
3662558793
|
|
|
:
|
: 3662558807
|
|
|
:
|
: 3662585634
|
|
|
:
|
: 9783662558799
|
|
|
:
|
: 9783662558805
|
|
|
:
|
: 9783662585634
|
|
|
:
|
3662558785
|
|
|
:
|
9783662558782
|
| Contents
|
:
|
Intro; Preface; References; Contents; 475 Chemistry and Structure-Activity Relationships of Psychedelics; Abstract; 1 Introduction; 2 Tryptamines; 2.1 Ring Substituents; 2.2 N-Alkylation; 2.3 Side Chain Alkylation; 3 Ergolines; 3.1 Amide Modifications of Lysergic Acid Derivatives; 3.2 N(6)-Alkyl Modifications of LSD; 4 Ergolines as "Research Chemicals"; 5 Phenethylamines and Related Congeners; 5.1 Beta-Oxygenated Phenethylamines; 5.2 Ring Substituents; 5.3 Methoxy Mimics-Benzofuran and Benzopyran Analogues; 5.4 Effect of Side Chain Alpha-Alkylation.
|
|
|
:
|
2 Clinical Relevance of the Interactions Between Glutamate and 5-HT2A Receptors in the mPFC3 Conclusions; References; 479 The Effects of Hallucinogens on Gene Expression; Abstract; 1 Introduction; 2 Immediate Early Genes; 3 IEG and 5-HT2A Receptor Expression: Early Studies; 4 Identification of Tissues that Transcriptionally Respond to Psychedelics: Early Studies; 5 IEG and 5-HT2A Receptor Expression in the Post-Genomic Era; 6 Psychedelics, Gene Expression, and Cellular Signaling; 7 Identification and Characterization of the Cortical Cellular Population Responsive to Psychedelics.
|
|
|
:
|
4 Role of Thalamocortical Inputs5 Brain Oscillations: Relevance to Schizophrenia; 6 Effects of Psychotomimetic Agents on Low Frequency Cortical Oscillations; 7 Mechanisms Involved in the Reversal by Antipsychotic Drugs; 8 Concluding Remarks; Acknowledgements; References; 480 Interactions of Hallucinogens with the Glutamatergic System: Permissive Network Effects Mediated Through Cortical Layer V Pyramidal Neurons; Abstract; 1 From 5-HT2A Receptor-Induced EPSCs and Recurrent Neuronal Activity to Salient Behavioral Effects Induced by 5-HT2A Receptor Activation.
|
|
|
:
|
5 Biased Agonism at the 5-HT2A Receptor6 Additional Signaling Pathways Modulated by Activation of the 5-HT2A Receptor; 7 Role of mGlu2 Receptor in Hallucinogen Action; 8 Future Directions; Acknowledgements; References; 473 Effects of Hallucinogens on Neuronal Activity; Abstract; 1 Hallucinogens as Pharmacological Models in Schizophrenia Research; 1.1 Serotonergic Hallucinogens; 1.2 NMDA Receptors. Noncompetitive Antagonists; 2 The Prefrontal Cortex; 3 Effects of Psychotomimetic Agents on Neuronal Activity in PFC; 3.1 Serotonergic Hallucinogens; 3.2 Noncompetitive NMDA Receptor Antagonists.
|
|
|
:
|
6 Identifying the "Active" Conformation of the Phenethylamines6.1 Effect of an N-Benzyl Group; 6.2 The Active Conformation of N-Benzylphenethylamines; 7 Modeling the Receptor-Ligand Interaction; 8 Conclusion; References; 478 Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways; Abstract; 1 Introduction to Receptor Pharmacology; 2 Serotonin and Serotonin Receptors: A Historical Perspective; 2.1 Serotonin; 2.2 Serotonin Receptors; 3 Chemical Neuroanatomy of 5-HT2A Receptors; 4 Hallucinogenic and Non-Hallucinogenic 5-HT2A Receptor Agonists.
|
| Abstract
|
:
|
This volume brings together the latest basic and clinical research examining the effects and underlying mechanisms of psychedelic drugs. Examples of drugs within this group include LSD, psilocybin, and mescaline. Despite their structural differences, these compounds produce remarkably similar experiences in humans and share a common mechanism of action. Commonalities among the substances in this family are addressed both at the clinical and phenomenological level and at the basic neurobiological mechanism level. To the extent possible, contributions relate the clinical and preclinical findings to one another across species. The volume addresses both the risks associated with the use of these drugs and the potential medical benefits that might be associated with these and related compounds.
|
| Subject
|
:
|
Clinical neuropsychology.
|
| Subject
|
:
|
Hallucinogenic drugs.
|
| Subject
|
:
|
Neurobiology.
|
| Subject
|
:
|
Clinical neuropsychology.
|
| Subject
|
:
|
Hallucinogenic drugs.
|
| Subject
|
:
|
MEDICAL-- Pharmacology.
|
| Subject
|
:
|
Neurobiology.
|
| Subject
|
:
|
Hallucinogens.
|
| Subject
|
:
|
Brain-- drug effects.
|
| Subject
|
:
|
Delusions-- chemically induced.
|
| Subject
|
:
|
Neurobehavioral Manifestations-- drug effects.
|
| Dewey Classification
|
:
|
615.7/883
|
| LC Classification
|
:
|
RM324.8
|
| NLM classification
|
:
|
QV 77.7
|
| Added Entry
|
:
|
Halberstadt, Adam L.
|
|
|
:
|
Nichols, David E.,1944-
|
|
|
:
|
Vollenweider, Franz X.
|